Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine SR in Children and Adolescents With Major Depressive Disorder
2008-001875-32Phase 3
- Sponsor
- Pfizer
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Desvenlafaxine SR with Placebo (2 arms). Primary endpoint: Change in CDRS-R total score from baseline to Week 8.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-001875-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001875-32.